Benzinga | Nov 10, 2021 04:42PM EST

C4 Therapeutics Q3 EPS $(0.51) Beats $(0.59) Estimate, Sales $8.50M Beat $7.61M Estimate

C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.59) by 13.56 percent. This is a 97.09 percent increase over losses of $(17.55) per share from the same period last year. The company reported quarterly sales of $8.50 million which beat the analyst consensus estimate of $7.61 million by 11.70 percent. This is a 0.63 percent increase over sales of $8.45 million the same period last year.